Form 4: Heron Therapeutics Executive Acquires Shares

Heron Therapeutics EVP, Chief Development Officer William P. Forbes acquired company stock through the vesting of restricted stock units.

Summary

• William P. Forbes, EVP, Chief Development Officer of Heron Therapeutics, Inc., acquired shares of common stock on April 30, 2026.
• The acquisition involved 11,694 shares and 11,770 shares, totaling 23,464 shares, through the vesting of restricted stock units (RSUs).
• These RSUs were granted on January 30, 2026, and vest in 16 equal quarterly installments, with the first installment occurring one quarter after the grant date.
• Following these transactions, Forbes beneficially owns 197,341 shares directly and 209,111 shares directly, with a portion of these being from vested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider stock acquisition can be positive, this specific transaction is a routine vesting of RSUs and does not represent a new investment or a significant change in beneficial ownership beyond what was previously planned.

Positives

• Executive leadership is acquiring company stock, which can signal confidence in the company's future prospects.
• The acquisition is a result of RSUs vesting, indicating a performance-based or retention incentive for the executive.

Future Outlook

The filing does not contain forward-looking statements or guidance. The transactions described are related to the vesting of previously granted restricted stock units.

Industry Context

StockSavvy.ai notes that insider transactions, such as this acquisition of shares by an executive, are common in the biotechnology and pharmaceutical sectors as a means of aligning executive interests with shareholder value. The vesting of RSUs is a standard component of executive compensation packages in this industry.

Stakeholder Impact

• Shareholders: The acquisition by an executive may be viewed positively as a sign of commitment, but it does not represent a new investment decision.
• Employees: The vesting of RSUs for executives is part of the compensation structure and does not directly impact other employees.
• Management: Reinforces the alignment of executive compensation with company stock performance.

Key Dates

Keywords

Heron Therapeutics, HRTX, Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, William P. Forbes, Executive Compensation, Beneficial Ownership